Novartis (NVS) to Report Q4 Earnings: Is a Beat in Store?
https://www.zacks.com/stock/news/2215142/novartis-nvs-to-report-q4-earnings-is-a-beat-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2215142
Jan 24, 2024 - Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.
0
Novartis (NVS) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
https://www.zacks.com/stock/news/2216430/novartis-nvs-q4-earnings-on-the-horizon-analysts-insights-on-key-performance-measures?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2216430
Jan 26, 2024 - Besides Wall Street's top -and-bottom-line estimates for Novartis (NVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
0
Bristol Myers (BMY), TSVT CAR T-Cell Therapy to Face FDA's ODAC
https://www.zacks.com/stock/news/2221922/bristol-myers-bmy-tsvt-car-t-cell-therapy-to-face-fda-s-odac?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2221922
Feb 06, 2024 - Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy.
0
Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals
https://www.zacks.com/stock/news/2224190/pharma-stock-roundup-azn-lly-s-q4-earnings-nvo-nvs-mrk-s-m-a-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-2224190
Feb 09, 2024 - Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements.
0
Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates
https://www.zacks.com/stock/news/2225655/incyte-s-incy-q4-earnings-revenues-fall-shy-of-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2225655
Feb 13, 2024 - Incyte's (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross the $1 billion mark for the first time on the continued growth of Jakafi and the strong launch of Opzelura.
0
Novartis (NVS) Declines More Than Market: Some Information for Investors
https://www.zacks.com/stock/news/2245727/novartis-nvs-declines-more-than-market-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2245727
Mar 25, 2024 - In the most recent trading session, Novartis (NVS) closed at $95.73, indicating a -0.52% shift from the previous trading day.
0
Novartis (NVS) to Undertake Job Cuts in Development Department
https://www.zacks.com/stock/news/2253912/novartis-nvs-to-undertake-job-cuts-in-development-department?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253912
Apr 11, 2024 - Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.
0
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
https://www.zacks.com/stock/news/2254812/novartis-nvs-inks-deal-for-arvn-s-prostate-cancer-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2254812
Apr 12, 2024 - Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
0